Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers.

Molecular cancer therapeutics - 1 Nov 2017

Zaman Guido J R, de Roos Jeroen A D M, Libouban Marion A A, Prinsen Martine B W, de Man Jos, Buijsman Rogier C, Uitdehaag Joost C M

Abstract excerpt

The spindle assembly checkpoint kinase TTK (Mps1) is a key regulator of chromosome segregation and is the subject of novel targeted therapy approaches by small-molecule inhibitors. Although the first TTK inhibitors have entered phase I dose escalating studies in combination with taxane chemotherapy, a patient stratification strategy is still missing. With the aim to identify a genomic biomarker to predict the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Hepatocellular

Share to Heterocyclic Compounds, 4 or More Rings

Share to Molecular Targeted Therapy

Share to Protein-Tyrosine Kinases

Share to Wnt Signaling Pathway

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28751540
DOI: 10.1158/1535-7163.MCT-17-0342

Genes

TTK
CTNNB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers.PMID 28751540Read ↗

Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancerSemantic proximity Read ↗

Harnessing AI to Reveal CTNNB1’s Central Role in Breast Cancer Progression and Drug DiscoverySemantic proximity Read ↗

MCAK Inhibitors Induce Aneuploidy in Triple Negative Breast Cancer ModelsSemantic proximity Read ↗

TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast CancerSemantic proximity Read ↗

MCAK Inhibitors Induce Aneuploidy in Triple Negative Breast Cancer ModelsSemantic proximity Read ↗

Molecular basis underlying resistance to Mps1/TTK inhibitors.Semantic proximity Read ↗

Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancersSemantic proximity Read ↗

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cellsSemantic proximity Read ↗

Tankyrase inhibition sensitizes cells to CDK4 blockadeSemantic proximity Read ↗

Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell divisionSemantic proximity Read ↗

Tankyrase inhibition sensitizes cells to CDK4 blockade.Semantic proximity Read ↗

CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.